Sampa Santra

List of Publications by Year
in descending order

#	Article	IF	Citations
1	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	11.0	308
2	Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. Journal of Virology, 2021, 95, .	3.4	6
3	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. Npj Vaccines, 2021, 6, 15.	6.0	5
4	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	6.0	46
5	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	4.7	2
6	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology, 2021, 22, 1294-1305.	14.5	20
7	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Npj Vaccines, 2020, 5, 107.	6.0	11
8	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. Npj Vaccines, 2020, 5, 36.	6.0	12
9	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathogens, 2020, 16, e1008377.	4.7	14
10	Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 2020, 11, 948.	12.8	27
11	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Cell Reports, 2020, 30, 1553-1569.e6.	6.4	21
12	Strong T _H 1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. Science Translational Medicine, 2019, 11, .	12.4	14
13	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	3.4	10
14	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	4.4	26
15	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nature Communications, 2018, 9, 2363.	12.8	46
16	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017, 543, 248-251.	27.8	699
17	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
18	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	12.8	137

#	Article	IF	Citations
19	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
20	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Reports, 2017, 21, 3681-3690.	6.4	97
21	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
22	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	8.2	41
23	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	6.1	47
24	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.8	6
25	Initiation of immune toleranceâ€"controlled HIV gp41 neutralizing B cell lineages. Science Translational Medicine, 2016, 8, 336ra62.	12.4	86
26	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
27	Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Open Forum Infectious Diseases, 2016, 3, ofw034.	0.9	15
28	Envelope residue 375 substitutions in simianâ€"human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3413-22.	7.1	170
29	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. Journal of Virology, 2016, 90, 5031-5046.	3.4	38
30	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
31	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight, 2016, 1, e88522.	5.0	10
32	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
33	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
34	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology, 2015, 475, 37-45.	2.4	25
35	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65
36	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. Vaccine, 2014, 32, 3995-4000.	3.8	4

#	Article	IF	Citations
37	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
38	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. Journal of Virology, 2013, 87, 1554-1568.	3.4	97
39	Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology, 2012, 428, 121-127.	2.4	46
40	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nature Medicine, 2010, 16, 324-328.	30.7	211
41	Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine, 2009, 27, 5837-5845.	3.8	44
42	A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10489-10494.	7.1	75
43	Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors. Journal of Virology, 2007, 81, 8563-8570.	3.4	38
44	Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. Journal of Virology, 2005, 79, 6516-6522.	3.4	136
45	Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11088-11093.	7.1	58
46	Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys. Journal of Immunology, 2002, 168, 1847-1853.	0.8	38
47	Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2002, 76, 6376-6381.	3.4	21
48	Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination. Journal of Virology, 2001, 75, 5151-5158.	3.4	186
49	B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. European Journal of Immunology, 2000, 30, 2650-2659.	2.9	28
50	Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination. Science, 2000, 290, 486-492.	12.6	876